Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1051164 | 0.87 | CREBBP (0.50) | CREBBPPOLBSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL29386752 | 0.87 | CREBBP (0.50) | CREBBPPOLBSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL19233806 | 0.77 | CREBBP (0.47) | CREBBPPOLBSMN1; SMN2GAAHTT | |
| SCHEMBL6587773 | 0.76 | PARP1 (0.46) | CREBBPSMN1; SMN2GAAHTTALDH1A1 | |
| SCHEMBL3552548 | 0.76 | HTR1B (0.48) | CREBBPPOLBSMN1; SMN2HTTALDH1A1 | |
| SCHEMBL30394690 | 0.76 | CREBBP (0.58) | CREBBPPOLBSMN1; SMN2GAAHTT | |
| SCHEMBL13806317 | 0.75 | POLB (0.54) | CREBBPPOLBSMN1; SMN2GAAHTT | |
| Hydrochloric Acid SCHEMBL17023503 | 0.73 | HTT (0.55) | CREBBPPOLBSMN1; SMN2GAAHTT | |
| SCHEMBL1333179 | 0.73 | HTT (0.54) | CREBBPPOLBSMN1; SMN2GAAHTT | |
| SCHEMBL887129 | 0.73 | HTT (0.54) | CREBBPPOLBSMN1; SMN2GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10138225-B2 | Amide compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9643986-B2 | Factor D inhibitors useful for treating inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017035351-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035352-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035349-A1 | AMIDE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015130806-A9 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2015130830-A9 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138225-B2 | Amide compounds for treatment of medical disorders | CFD, TFPI, CFH | CREBBP 1244/4885POLB 3951/4885SMN1; SMN2 2811/4885 |
| US-20190144473-A1 | AMINO COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C9 | CREBBP 2836/4885POLB 4098/4885SMN1; SMN2 1331/4885 |
| US-20160362398-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, CFH | CREBBP 1831/4885POLB 3554/4885SMN1; SMN2 2038/4885 |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | CREBBP 2836/4885POLB 4098/4885SMN1; SMN2 1331/4885 |
| US-10370394-B2 | Carbamate, ester, and ketone compounds for treatment of complement mediated disorders | CFD, C9, CFH | CREBBP 724/4885POLB 4453/4885SMN1; SMN2 2371/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | CREBBP 1831/4885POLB 3554/4885SMN1; SMN2 2038/4885 |
| US-10660876-B2 | Amino compounds for treatment of medical disorders | CFD, CFH, F12 | CREBBP 3434/4885POLB 3828/4885SMN1; SMN2 1899/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | CREBBP 1853/4885POLB 3987/4885SMN1; SMN2 1358/4885 |
| US-20150239893-A1 | Amide Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | CREBBP 1853/4885POLB 3987/4885SMN1; SMN2 1358/4885 |
| US-20170298085-A1 | CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, CFH | CREBBP 724/4885POLB 4453/4885SMN1; SMN2 2371/4885 |
| US-20180177761-A1 | AMINO COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, CFH, F12 | CREBBP 3434/4885POLB 3828/4885SMN1; SMN2 1899/4885 |
| US-10689409-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | CREBBP 2836/4885POLB 4098/4885SMN1; SMN2 1331/4885 |
| US-20170057950-A1 | Amide Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | CREBBP 1244/4885POLB 3951/4885SMN1; SMN2 2811/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | CREBBP 2836/4885POLB 4098/4885SMN1; SMN2 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.